MIDAZOLAM INJECTION 1 MG
MIDAZOLAM (MIDAZOLAM HYDROCHLORIDE) : 1 MG · DIN 02243934 · NOVOPHARM LIMITED
Health Canada status: CANCELLED POST MARKET
What is MIDAZOLAM INJECTION?
MIDAZOLAM INJECTION 1 MG contains MIDAZOLAM (MIDAZOLAM HYDROCHLORIDE) : 1 MG. It is listed in the Health Canada Drug Product Database under DIN 02243934, held by NOVOPHARM LIMITED, supplied as SOLUTION for INTRAMUSCULAR ; INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 02-May-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is MIDAZOLAM INJECTION used for?
IM premedication; IV sedation/anxiolysis/amnesia for short diagnostic/endoscopic procedures; induction of anesthesia; continuous IV infusion for sedation in intubated ICU patients.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
What else is MIDAZOLAM INJECTION called?
The same molecule, MIDAZOLAM, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| BUCCOLAM | Latin | Czechia, Sweden |
| Dormicum | Latin | Czechia, Morocco, South Africa |
| MIDAZOLAM | Latin | Brazil |
| Midazolam Kalceks | Latin | Bahrain, Czechia, Saudi Arabia |
| Zyamis | Latin | Australia |
| Midanium | Latin | Morocco, South Africa |
| MIDAZOLAM ACCORD | Latin | Czechia |
| Midazolam Medical Valley | Latin | Sweden |
| Midazolam Panpharma | Latin | Norway |
| DORMIUM | Latin | Brazil |
| MIDAZOLAM HAMELN | Latin | Czechia |
| DORMONID | Latin | Brazil |
| Oroxelam | Latin | Saudi Arabia |
| HYPOZAM | Latin | Brazil |
| Micro-Midazolam | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02243934 |
|---|---|
| Brand name | MIDAZOLAM INJECTION |
| Generic / active ingredient | MIDAZOLAM (MIDAZOLAM HYDROCHLORIDE) : 1 MG |
| Manufacturer | NOVOPHARM LIMITED |
| Strength | 1 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRAMUSCULAR ; INTRAVENOUS |
| Schedule | TARGETED SUBSTANCES (CDSA IV) |
| ATC code | N05CD08 MIDAZOLAM |
| AHFS class | 28:24.08 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 02-May-2018 |
| Original market date | 2001-12-17 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02243934 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2243934 |
| Brand name | MIDAZOLAM INJECTION |
| Active ingredient / INN | MIDAZOLAM (MIDAZOLAM HYDROCHLORIDE) : 1 MG |
| ATC code | N05CD08 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N05 |
| AHFS class | 28:24.08 |
| Health Canada schedule | TARGETED SUBSTANCES (CDSA IV) |
| Biosimilar biologic | No |
| Market authorization holder | NOVOPHARM LIMITED |
How is it administered?
Adult sedation: initial dose 1-2.5 mg IV titrated slowly. Pediatric: calculated on mg/kg basis and titrated. ICU: continuous infusion titrated to effect. Do not use rapid IV injection.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not specified in the provided text.
How is it supplied?
Not explicitly detailed in text (mentions 1 mg/mL and 5 mg/mL strengths).
Which pack is which?
| Strength on the label | 1 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAMUSCULAR ; INTRAVENOUS |
| Packaging as described in the monograph | Not explicitly detailed in text (mentions 1 mg/mL and 5 mg/mL strengths). |
| Storage | Not specified in the provided text. |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Contraindications
Hypersensitivity to benzodiazepines; acute pulmonary insufficiency; severe chronic obstructive pulmonary disease (COPD); acute narrow angle glaucoma.
Warnings and precautions
Risk of fatal respiratory depression/arrest. Use only with continuous monitoring (pulse oximetry) and resuscitation equipment. Must be titrated; avoid single bolus/rapid IV administration.
Is MIDAZOLAM in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by FRESENIUS KABI CANADA LTD, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code N05CD08 MIDAZOLAM. 14 of 32 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| BUCCOLAM | 10 MG / 2 ML | SOLUTION | NEURAXPHARM PHARMACEUTICALS, S.L. | MARKETED | DIN 02559609 |
| BUCCOLAM | 2.5 MG / 0.5 ML | SOLUTION | NEURAXPHARM PHARMACEUTICALS, S.L. | MARKETED | DIN 02559579 |
| BUCCOLAM | 5 MG / 1 ML | SOLUTION | NEURAXPHARM PHARMACEUTICALS, S.L. | MARKETED | DIN 02559587 |
| BUCCOLAM | 7.5 MG / 1.5 ML | SOLUTION | NEURAXPHARM PHARMACEUTICALS, S.L. | MARKETED | DIN 02559595 |
| MIDAZOLAM INJECTION | 1 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02240285 |
| MIDAZOLAM INJECTION | 5 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02240286 |
| MIDAZOLAM INJECTION USP | 1 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 02382342 |
| MIDAZOLAM INJECTION USP | 1 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 02382377 |
| MIDAZOLAM INJECTION USP | 1 MG | SOLUTION | STERINOVA INC. | MARKETED | DIN 02498022 |
| MIDAZOLAM INJECTION USP | 1 MG | SOLUTION | HIKMA CANADA LIMITED | MARKETED | DIN 02553104 |
Who else supplies MIDAZOLAM worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. MIDAZOLAM appears in 146 registered pack listings across 14 markets, published on 12 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does MIDAZOLAM cost around the world?
MIDAZOLAM is listed on 19 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Bahrain publishes a retail (max); Brazil publishes a preco fabrica (ex-factory ceiling). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| South Africa | single exit price | 22 | 29 | ZAR███.██ |
| United States | acquisition | 5 | 18 | USD███.██ |
| Brazil | preco fabrica (ex-factory ceiling) | 5 | 16 | BRL███.██ |
| Czechia | max producer price (ex-factory) | 5 | 16 | CZK███.██ |
| Romania | max producer price | 11 | 15 | RON███.██ |
| Saudi Arabia | public | 11 | 15 | SAR███.██ |
| Sweden | AIP (pharmacy purchase price) | 2 | 10 | SEK███.██ |
| Australia | ex-manufacturer | 2 | 9 | AUD███.██ |
| Italy | prezzo al pubblico (classe A) | 8 | 8 | EUR███.██ |
| Italy | ex-factory (classe H) | 6 | 8 | EUR███.██ |
| United Kingdom | hospital | 7 | 7 | GBP███.██ |
| Greece | producer price (ex-factory) | 7 | 7 | EUR███.██ |
| United Arab Emirates | public | 5 | 5 | AED███.██ |
| Morocco | PPV (public price) | 3 | 5 | MAD███.██ |
| Norway | max AUP (pharmacy retail) | 2 | 5 | NOK███.██ |
| Spain | PVP con IVA (public price) | 4 | 4 | EUR███.██ |
| Hungary | producer price (ex-factory) | 4 | 4 | HUF███.██ |
| Luxembourg | reimbursement | 4 | 4 | EUR███.██ |
| Slovakia | categorised final price | 4 | 4 | EUR███.██ |
| Bahrain | retail (max) | 1 | 2 | BHD███.██ |
191 pack listings across 118 brand entries and 18 price bases, refreshed 08 Sep 2026. Ranges span every MIDAZOLAM pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.